

Literatura ACTA MEDICINAE 10/2022 Revmatologie

- 2 **Upadacitinib nebo abatacept v léčbě revmatoidní artritidy – komentář ke studii SELECT CHOICE**
prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha
- 2 **Zkušenosti s biosimilárními léky v registru ATTRA**
doc. MUDr. Petr Bradna, CSc. | MUDr. Renata Rouhová | Mgr. Lucie Nekvindová, Ph.D. II. interní gastroenterologická klinika, FN a LF Hradec Králové, Institut biostatistiky a analýz, Brno
- 2 **Přínos blokády IL-6 pro snížení glykemie a inzulínové rezistence u pacientů s revmatoidní artritidou**
doc. MUDr. Jakub Závada, Ph.D. Revmatologický ústav, Praha
- 2 **Covid-19 a revmatická onemocnění – zkušenosti po více než dvou letech**
prof. MUDr. Ladislav Šenolt, Ph.D. Revmatologický ústav Praha
- 3 **JAK inhibitory v léčbě revmatických onemocnění – reportáž**
doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha
- 4 **Pacienti léčení secukinumabem (Cosentyx) – kazuistiky**
prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha
- 4 **Terapeutický přínos tofacitinibu u nemocných s juvenilní idiopatickou artritidou**
doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha
- 4 **Tofacitinib a riziko vzniku nádorů: výsledky studie STAR-RA u nemocných s revmatoidní artritidou**
doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha
- 4 **Subkutánní metotrexát v léčbě revmatoidní artritidy**
doc. MUDr. Mária Filková, Ph.D. Revmatologický ústav, Praha
- 5 **Risankizumab v léčbě psoriatické artritidy**
prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha
- 5 **Biobetter – novinka (nejen) u revmatologů – reportáž**
- 5 **Biobetters – nový pojem v oblasti biologických léků**
doc. MUDr. Karel Urbánek, Ph.D. Ústav farmakologie LF UP a FN Olomouc
- 5 **Filgotinib – novinka v léčbě pacientů s revmatoidní artritidou – reportáž**
- 5 **Metamizol v léčbě muskuloskeletální bolesti**
MUDr. Marta Olejárová, CSc. Revmatologický ústav a Revmatologická klinika 1. LF UK, Praha
- 6 **Význam včasného zahájení biologické léčby u pacientů s revmatoidní artritidou**
MUDr. Radoslav Roman II. interní klinika, revmatologická ambulance, Fakultní nemocnice u sv. Anny v Brně
- 6 **Dieta a revmatická onemocnění**
MUDr. Jiří Vejmelka Interní klinika 3. LF UK a FTN, Praha
Mgr. Lucie Růžičková vedoucí nutriční terapeutka VFN, Praha
doc. MUDr. Pavel Kohout, Ph.D. Interní klinika 3. LF UK a FTN, Praha

Upadacitinib nebo abatacept v léčbě revmatoidní artritidy – komentář ke studii SELECT CHOICE

prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha

- 1 Parmentier, J. M. – Voss, J. – Graff, C., et al.: In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). *BMC Rheumatology*, 2018, 2, s. 23.
- 2 Fleischmann, R. – Pangan, A. L. – Song, I. H., et al.: Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. *Arthritis Rheumatol*, 2019, 71, s. 1788–1800.
- 3 Genovese, M. C. – Fleischmann, R. – Combe, B., et al.: Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. *Lancet*, 2018, 391, s. 2513–2524.
- 4 Smolen, J. S. – Pangan, A. L. – Emery, P., et al.: Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. *Lancet*, 2019, 393, s. 2303–2311.
- 5 van Vollenhoven, R. – Takeuchi, T. – Pangan, A. L., et al.: Efficacy and safety of upadacitinib monotherapy in methotrexate naive patients with moderately to severely active rheumatoid arthritis (SELECT-EARLY): a randomized, double-blind, active-comparator, multi-center, multi-country trial. *Arthritis Rheumatol*, 2020, 72, s. 1607–1620.
- 6 Smolen, J. S. – Burmester, G. R. – Combe, B., et al.: Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXCELERATE study. *Lancet*, 2016, 388, s. 2763–2774.
- 7 Burmester, G. R. – Lin, Y. – Patel, R., et al.: Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. *Ann Rheum Dis*, 2017, 76, s. 840–847.
- 8 Schiff, M. – Keiserman, M. – Codding, C., et al.: Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. *Ann Rheum Dis*, 2008, 67, s. 1096–1103.
- 9 Taylor, P. C. – Keystone, E. C. – van der Heijde, D., et al.: Baricitinib versus placebo or adalimumab in rheumatoid arthritis. *N Engl J Med*, 2017, 376, s. 652–662.
- 10 Fleischmann, R. – Mysler, R. – Hall, S., et al.: Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL STRATEGY): a phase 3b/4, double blind, head to head, randomised controlled trial. *Lancet*, 2017, 390, s. 457–507.
- 11 Roth, A. R. – Enejosa, J. – Pangan, A. L., et al.: Trial of upadacitinib or abatacept in rheumatoid arthritis. *N Engl J Med*, 2020, 383, s. 1511–1521.
- 12 Smolen, J. – Landewe, R. – Bijlsma, J. W. L., et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease modifying antirheumatic drugs: 2019 update. *Ann Rheum Dis*, 2020, 79, s. 685–699.
- 13 Winthrop, K. L. – Yamanaka, H. – Valdez, H., et al.: Herpes zoster and tofacitinib in patients with rheumatoid arthritis. *Arthritis Rheumatol*, 2014, 66, s. 2657–2684.
- 14 Cohen, S. B. – Tanaka, Y. – Mariette, X., et al.: Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. *Ann Rheum Dis*, 2017, 76, s. 1253–1262.
- 15 Nash, P. – Kerschbaumer, A. – Dörner, T., et al.: Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. *Ann Rheum Dis*, 2021, 80, s. 71–87.
- 16 Winthrop, K. L.: The emerging safety profile of JAK inhibitors in rheumatic diseases. *Rev Rheumatol*, 2017, 13, s. 234–243.
- 17 Traves, P. G. – Murray, B. – Campigotto, F.: JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. *Ann Rheum Dis*, 2021, 80, s. 865–875.
- 18 Rubbert-Roth, A. – Enejosa, J. – Pangan, A., et al.: SAT0151 efficacy and safety of upadacitinib versus abatacept in patients with active rheumatoid arthritis and prior inadequate response or intolerance to biologic disease-modifying anti-rheumatic drugs (SELECT-CHOICE): a double-blind, randomized controlled phase 3 trial. *Ann Rheum Dis*, 2020, 79, s. 1015–1016.

Zkušenosti s biosimilárními léky v registru ATTRA

doc. MUDr. Petr Bradna, CSc. | MUDr. Renata Rouhová | Mgr. Lucie Nekvindová, Ph.D. II. interní gastroenterologická klinika, FN a LF Hradec Králové, Institut biostatistiky a analýz, Brno

- 1 Vetchy, D. – Vetcha, M.: Biosimilars – similar biotherapeutic agents. *Remedia*, 2010, 20, s. 74–77.
- 2 European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology – derived proteins as active substance: non-clinical and clinical issues. 2014, s. 1–13. Dostupné z: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-2.pdf, vyhledáno 12. 7. 2022.
- 3 Smolen, J. S. – Goncalves, J. – Quinn, M., et al.: Era of biosimilars in rheumatology: reshaping the healthcare environment. doi: [10.1136/rmdopen-2019-000900](https://doi.org/10.1136/rmdopen-2019-000900).
- 4 Smolen, J. S. – Landewe, R. B. M. – Bijlsma, J. W. J., et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. *Ann Rheum Dis*, 2020, 79, s. 685–699.
- 5 Huizinga, T. W. J. – Torii, Y. – Muniz, R.: Adalimumab biosimilars in the treatment of rheumatoid arthritis: a systematic review of the evidence for biosimilarity. *Rheumatol Ther*, 2021, 8, s. 41–61.
- 6 Ishii-Watabe, A. – Kuwabara, T.: Biosimilarity assessment of biosimilar therapeutic monoclonal antibodies. *Drug Metab Pharmacokinet*, 2019, 34, s. 64–70.
- 7 Pavelka, K.: Biosimilární léky. In: Pavelka, K. – Vencovsky, J. – Horák, P., et al.: *Revmatologie*. Maxdorf, Praha, 2018, s. 289–297.
- 8 Barszczewska, O. – Piechota, A.: The impact of introducing successive biosimilars on changes in prices of adalimumab, infliximab, and trastuzumab – Polish experiences. *Int J Environ Res Public Health*, 2021, 18, s. 6952.
- 9 Waller, J. – Sullivan, E. – Piercy, J., et al.: Assessing physician and patient acceptance of infliximab biosimilars in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis across Germany. *Patient Prefer Adherence*, 2017, 11, s. 519–530.
- 10 Státní ústav pro kontrolu léčiv, dostupné z: <https://www.sukl.cz/modules/medication/search.php>, vyhledáno 12. 7. 2022.
- 11 Pelech, E. – Kaltsonoudis, E. – Voulgari, P. V., et al.: Biosimilars and retention rates in patients with ankylosing spondylitis. *Clin Exp Rheumatol*, 2021, 39, s. 440.
- 12 Tweehuisen, L. – van den Bemt, B. J. F. – van Ingen, I. L., et al.: Subjective complaints as the main reason for biosimilar discontinuation after open-label transition from reference infliximab to biosimilar infliximab. *Arthritis Rheumatol*, 2018, 70, s. 60–68.
- 13 Nabi, H. – Georgiadis, S. – Loft, A. G.: Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial. *Ann Rheum Dis*, 2021, 80, s. 1400–1409.
- 14 Graudal, N. – Kaas-Hansen, B. S. – Guskı, L., et al.: Different original and biosimilar TNF inhibitors similarly reduce joint destruction in rheumatoid arthritis – a network meta-analysis of 36 randomized controlled trials. *Int J Mol Sci*, 2019, 20, s. 4350–4369.
- 15 Lu, X. – Hu, R. – Peng, L., et al.: Efficacy and safety of adalimumab biosimilars: current critical clinical data in rheumatoid arthritis. *Front Immunol*, 2021, <https://doi.org/10.3389/fimmu.2021.638444>.
- 16 Kay, J. J.: A 'wind of change' to biosimilars: The NOR-SWITCH trial and its extension. *Intern Med*, 2019, 285, s. 693–695.
- 17 Baji, P. – Pentek, B. – Czirik, L., et al.: Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison. *Eur J Health Econ*, 2014, 15, suppl. 1, s. S53–S64.
- 18 Lindström, U. – Glintborg, B. – Di Giuseppe, D., et al.: Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naive patients with spondyloarthritis. *RMD Open*, 2019, s. e001079, dostupné z: <https://rmdopen.bmj.com/content/5/2/e001079>, vyhledáno 12. 7. 2022.

Přínos blokády IL-6 pro snížení glykemie a inzulínové rezistence u pacientů s revmatoidní artritidou

doc. MUDr. Jakub Závada, Ph.D. Revmatologický ústav, Praha

- 1 Akbari, M., et al.: IL-6 signalling pathways and the development of type 2 diabetes. *Inflammopharmacology*, 2018, 26, s. 685–698.
- 2 Pradhan, A. D., et al.: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. *JAMA*, 2001, 286, s. 327–334.
- 3 Bowker, N., et al.: Meta-analysis investigating the role of interleukin-6 mediated inflammation in type 2 diabetes. *Ebio Medicine*, 2020, 61, s. 103062.
- 4 Cupido, A. J., et al.: Dissecting the IL-6 pathway in cardiometabolic disease: A Mendelian randomization study on both IL6 and IL6R. *Br J Clin Pharmacol*, 2022, 88, s. 2875–2884.
- 5 Solomon, D. H., et al.: Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. *JAMA*, 2011, 305, s. 2525–2531.
- 6 Baker, J. F., et al.: Disease activity, cytokines, chemokines and the risk of incident diabetes in rheumatoid arthritis. *Ann Rheum Dis*, 2021, 80, s. 566–572.
- 7 Genovese, M. C., et al.: Interleukin-6 receptor blockade or TNF α inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials. *Arthritis Res Ther*, 2020, 22, s. 206.

Covid-19 a revmatická onemocnění – zkušenosti po více než dvou letech

prof. MUDr. Ladislav Šenolt, Ph.D. Revmatologický ústav Praha

- 1 Zylke, J. W. – Bauehner, H.: Mortality and morbidity: the measure of a Pandemic. *JAMA*, 2020, 324, s. 458–459.
- 2 Wang, Q. – Liu, J. – Shao, R., et al.: Risk and clinical outcomes of COVID-19 in patients with rheumatic diseases compared with the general population: a systematic review and meta-analysis. *Rheumatol Int*, 2021, 41, s. 851–861.
- 3 Listing, J. – Gerhold, K. – Zink, A.: The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. *Rheumatology*, 2013, 52, s. 53–61.

- 4 Akiyama, S. – Hamdeh, S. – Micic, D., et al.: Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. *Ann Rheum Dis*, 2021, 80, s. 384–391.
- 5 Kroon, F. P. B. – Najm, A. – Alunno, A., et al.: Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations. *Ann Rheum Dis*, 2022, 81, s. 422–432.
- 6 Osuchowski, M. F. – Winkler, M. S. – Skirecki, T., et al.: The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. *Lancet Respir Med*, 2021, 9, s. 622–642.
- 7 Rutter, M. – Lanyon, P. C. – Grainge, M. J., et al.: COVID-19 infection, admission and death amongst people with rare autoimmune rheumatic disease in England. Results from the REORDER Project. *Rheumatology*, 2021, keab794, doi: 10.1093/rheumatology/keab794.
- 8 Strangfeld, A. – Schäfer, M. – Gianfrancesco, M. A., et al.: COVID-19 Global Rheumatology Alliance: Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. *Ann Rheum Dis*, 2021, 80, s. 930–942.
- 9 D'Silva, K. M. – Jorge, A. – Cohen, A., et al.: COVID-19 outcomes in patients with systemic autoimmune rheumatic diseases compared to the general population: a US multicenter, comparative cohort study. *Arthritis Rheumatol*, 2021, 73, s. 14–920.
- 10 FAI2R/SFR/SNFI/SOFREMIP/CRIM/IMMEDIATE consortium and contributors: Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients. *Ann Rheum Dis*, 2020, 80, s. 527–538.
- 11 Bower, H. – Frisell, T. – Di Giuseppe, D., et al.: ARTIS Study Group: Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study. *Ann Rheum Dis*, 2021, 80, s. 1086–1093.
- 12 Fagni, F. – Simon, D. – Tascilar, K., et al.: COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses. *Lancet Rheumatol*, 2021, 3, s. e724–e736.
- 13 Schulze-Koops, H. – Krueger, K. – Vallbracht, I., et al.: Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab. *Ann Rheum Dis*, 2021, 80, s. e67.
- 14 Sparks, J. A. – Wallace, Z. S. – Seet, A. M., et al.: COVID-19 Global Rheumatology Alliance: Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. *Ann Rheum Dis*, 2021, 80, s. 1137–1146.
- 15 Tang, K. T. – Hsu, B. C. – Chen, D. Y.: Autoimmune and rheumatic manifestations associated with COVID-19 in adults: an updated systematic review. *Front Immunol*, 2021, 12, s. 645013.
- 16 Foret, T. – Dufrost, V. – Salomon Du Mont, L., et al.: Systematic review of antiphospholipid antibodies in COVID-19 patients: culprits or bystanders? *Curr Rheumatol Rep*, 2021, 23, s. 65.
- 17 Schenker, H. M. – Hagen, M. – Simon, D., et al.: Reactive arthritis and cutaneous vasculitis after SARS-CoV-2 infection. *Rheumatology*, 2021, 60, s. 479–480.
- 18 Zacharias, H. – Dubey, S. – Koduri, G., et al.: Rheumatological complications of Covid 19. *Autoimmun Rev*, 2021, 20, s. 102883.
- 19 Ahmed, S. – Zimba, O. – Gasparyan, A. Y.: COVID-19 and the clinical course of rheumatic manifestations. *Clin Rheumatol*, 2021, 40, s. 2611–2619.
- 20 Pavli, A. – Theodoridou, M. – Maltezos, H. C.: Post-COVID syndrome: incidence, clinical spectrum, and challenges for primary healthcare professionals. *Arch Med Res*, 2021, 52, s. 575–581.
- 21 Metyas, S. – Chen, C. – Aung, T., et al.: Rheumatologic manifestations of post SARS-CoV-2 infection: a case series. *Curr Rheumatol Rev*, 2022, doi: 10.2174/1573397118666220211155716.
- 22 Jiang, L. – Tang, K. – Levin, M., et al.: COVID-19 and multisystem inflammatory syndrome in children and adolescents. *Lancet Infect Dis*, 2020, 20, s. e276–e288.
- 23 Furer, V. – Evliatar, T. – Zisman, D., et al.: Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. *Ann Rheum Dis*, 2021, 80, s. 1330–1338.
- 24 Simon, D. – Tascilar, K. – Fagni, F., et al.: SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases. *Ann Rheum Dis*, 2021, 80, s. 1312–1316.
- 25 Spiera, R. – Jinich, S. – Jannat-Khah, D.: Rituximab, but not other anti-rheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases. *Ann Rheum Dis*, 2021, 80, s. 1357–1359.
- 26 Seror, R. – Camus, M. – Salmon, J. H., et al.: Do JAK inhibitors affect immune response to COVID-19 vaccination? Data from the MAJIK-SFR Registry. *Lancet Rheumatol*, 2022, 4, s. e8–e11.
- 27 Paik, J. J. – Sparks, J. A. – Kim, A. H. J.: Immunogenicity, breakthrough infection, and underlying disease flare after SARS-CoV-2 vaccination among individuals with systemic autoimmune rheumatic diseases. *Curr Opin Pharmacol*, 2022, 65, s. 102243.
- 28 Krasselt, M. – Wagner, U. – Nguyen, P., et al.: Humoral and cellular response to COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases under real-life conditions. *Rheumatology*, 2022, keac089, doi: 10.1093/rheumatology/keac089.
- 29 Syversen, S. W. – Jyssum, I. – Tveter, A. T., et al.: Immunogenicity and safety of standard and third-dose SARS-CoV-2 vaccination in patients receiving immunosuppressive therapy. *Arthritis Rheumatol*, 2022, doi: 10.1002/art.42153.
- 30 Machado, P. M. – Lawson-Tovey, S. – Strangfeld, A., et al.: Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. *Ann Rheum Dis*, 2021, annrheumdis-2021-221490, doi: 10.1136/annrheumdis-2021-221490.
- 31 Liew, J. – Gianfrancesco, M. – Harrison, C., et al.: SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry. *RMD Open*, 2022, 8, s. e002187.
- 32 Bieber, A. – Sagy, I. – Novack, L., et al.: BNT162b2 mRNA COVID-19 vaccine and booster in patients with autoimmune rheumatic diseases: a national cohort study. *Ann Rheum Dis*, 2022, doi: 10.1136/annrheumdis-2021-221824.
- 33 Accorsi, E. K. – Britton, A. – Fleming-Dutra, K. E., et al.: Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 omicron and delta variants. *JAMA*, 2022, 327, s. 639–651.
- 34 Abu-Raddad, L. J. – Chemaitelly, H. – Ayoub, H. H., et al.: Effect of mRNA vaccine boosters against SARS-CoV-2 omicron infection in Qatar. *N Engl J Med*, 2022, 386, s. 1804–1816.
- 35 Barbhayya, M. – Levine, J. M. – Bykerk, V. P., et al.: Systemic rheumatic disease flares after SARS-CoV-2 vaccination among rheumatology outpatients in New York City. *Ann Rheum Dis*, 2021, 80, s. 1352–1354.
- 36 Spinelli, F. R. – Favalli, E. G. – Garufi, C., et al.: Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine. *Arthritis Res Ther*, 2022, 24, s. 21.
- 37 Connolly, C. M. – Ruddy, J. A. – Boyarsky, B. J., et al.: Disease flare and reactivity in patients with rheumatic and musculoskeletal diseases following two-dose SARS-CoV-2 messenger RNA vaccination. *Arthritis Rheumatol*, 2022, 74, s. 28–32.
- 38 Kawano, Y. – Patel, N. J. – Wang, X., et al.: Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: From the first wave to Omicron. *medRxiv*, 2022, doi: https://doi.org/10.1101/2022.06.19.22276599.
- 39 Grainger, R. – Kim, A. H. J. – Conway, R., et al.: COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations. *Nat Rev Rheumatol*, 2022, 18, s. 191–204.
- 40 Šenolt, L., et al.: Výbor České Revmatologické Společnosti ČLS JEP: Covid-19, očkování proti SARS-CoV-2 a antivirová léčba u revmatických onemocnění – přepracované stanovisko ČRS ČLS JEP. *Čes Revmatol*, 2022, 30, s. 9–18.
- 41 Borio, L. L. – Bright, R. A. – Emanuel, E. J.: A national strategy for COVID-19 medical countermeasures: vaccines and therapeutics. *JAMA*, 2022, 327, s. 215–216.

JAK inhibitory v léčbě revmatických onemocnění – reportáž

doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha

- 1 Schett, G. – McInnes, I. B. – Neurath, M. F.: Reframing immune-mediated inflammatory diseases through signature cytokine hubs. *N Engl J Med*, 2021, 385, s. 628–639.
- 2 Smolen, J. S. – Landewé, R. B. M. – Bijlsma, J. W. J., et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. *Ann Rheum Dis*, 2020, 79, s. 685–699.
- 3 Fraenkel, L. – Bathon, J. M. – England, B. R., et al.: 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Care Res*, 2021, 73, s. 924–939.
- 4 Smolen, J. S. – Aletaha, D. – Bijlsma, J. W., et al.: Treating rheumatoid arthritis to target: recommendations of an international task force. *Ann Rheum Dis*, 2010, 69, s. 631–637.
- 5 Smolen, J. S. – Schöls, M. – Braun, J., et al.: Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. *Ann Rheum Dis*, 2018, 77, s. 3–17.
- 6 Molto, A. – López-Medina, C. – Van den Bosch, F. E., et al.: Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial. *Ann Rheum Dis*, 2021, 80, s. 1436–1444.
- 7 Coates, L. C. – Moverley, A. R. – McParland, L., et al.: Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. *Lancet*, 2015, 386, s. 2489–2498.
- 8 Yu, C. – Jin, S. – Wang, Y., et al.: Remission rate and predictors of remission in patients with rheumatoid arthritis under treat-to-target strategy in real-world studies: a systematic review and meta-analysis. *Clin Rheumatol*, 2019, 38, s. 727–738.
- 9 van Vollenhoven, R. – Takeuchi, T. – Pangan, A. L., et al.: Efficacy and safety of upadacitinib monotherapy in methotrexate-naïve patients with moderately-to-severely active rheumatoid arthritis (SELECT-EARLY): a multicenter, multi-country, randomized, double-blind, active comparator-controlled trial. *Arthritis Rheumatol*, 2020, 72, s. 1607–1620.
- 10 McInnes, I. B. – Thompson, L. – Giles, J., et al.: Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. *Ann Rheum Dis*, 2015, 74, s. 694–702.
- 11 McInnes, I. B. – Schett, G.: The pathogenesis of rheumatoid arthritis. *N Engl J Med*, 2011, 365, s. 2205–2219.
- 12 Sokka, T., et al.: Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA Study. *Arthritis Res Ther*, 2010, 12, s. R42.
- 13 Kim, D. – Kaneko, Y. – Takeuchi, T., et al.: Importance of obtaining remission for work productivity and activity of patients with rheumatoid arthritis. *J Rheum*, 2017, 44, s. 1112–1117.
- 14 Listing, J., et al.: The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. *Rheumatology*, 2013, 52, s. 53–61.
- 15 Solomon, D. H., et al.: Disease activity in rheumatoid arthritis and the risk of cardiovascular events. *Arthritis Rheum*, 2015, 67, s. 1449–1455.
- 16 Linde, L., et al.: Does clinical remission lead to normalization of EQ-5D in patients with rheumatoid arthritis and is selection of remission criteria important? *J Rheumatol*, 2010, 37, s. 285–290.
- 17 Baeklund, E., et al.: Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. *Arthritis Rheum*, 2006, 54, s. 692–701.
- 18 Kekow, J., et al.: Improvements in patient-reported outcomes, symptoms of depression and anxiety, and their association with clinical remission among patients with moderate-to-severe active early rheumatoid arthritis. *Rheumatology*, 2011, 50, s. 401–409.
- 19 Nikiphorou, E., et al.: Association between rheumatoid arthritis disease activity, progression of functional limitation and long-term risk of orthopaedic surgery: combined analysis of two prospective cohorts supports EULAR treat to target DAS thresholds. *Ann Rheum Dis*, 2016, 75, s. 2080–2086.
- 20 Accortt, N. A., et al.: Impact of sustained remission on the risk of serious infection in patients with rheumatoid arthritis. *Arthritis Care Res*, 2018, 70, s. 679–684.
- 21 Fleischmann, R. M., et al.: Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. *Arthritis Rheumatol*, 2019, 71, s. 1788–1800.
- 22 Fleischmann, R. M., et al.: Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. *Ann Rheum Dis*, 2019, 78, s. 1454–1462.
- 23 Fleischmann, R. M., et al.: Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. *Lancet*, 2017, 390, s. 457–468.
- 24 Taylor, P. C., et al.: Baricitinib versus placebo or adalimumab in rheumatoid arthritis. *N Engl J Med*, 2017, 376, s. 652–662.
- 25 Combe, B., et al.: Thu0198 efficacy and safety of filgotinib for patients with rheumatoid arthritis with inadequate response to methotrexate: finch 1 52-week results. *Ann Rheum Dis*, 2020, 79, suppl. 1, s. 316.

Pacienti léčení secukinumabem (Cosentyx) – kazuistiky

prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha

- 1 **Feldman, M., et al.**: Anti-TNF therapy useful in RA and Crohn's disease analysis of the mechanism of action predicts utility in other diseases. *Transplant Proc*, 1998, 30, s. 4126–4127.
- 2 **Wendling, D., et al.**: Paradoxical effects of anti-TNF alpha agents in inflammatory diseases. *Expert Rev Clin Immunol*, 2014, 1, s. 159–169.
- 3 **Li, S. J., et al.**: TNF inhibitor-induced psoriasis: proposed algorithm for treatment and management. *J Psoriasis Psoriatic arthritis*, 2019, 4/2, s. 70–80.
- 4 **Nguyen, K. – Vleugels, R. A. – Velez, N. F., et al.**: Psoriasisform reactions to anti-tumor necrosis factor therapy. *J Clin Rheumatol*, 2013, s. 377–381.
- 5 **Harrison, M. J., et al.**: Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving antitumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. *Ann Rheum Dis*, 2009, 68, s. 209–215.
- 6 **Collemer, A. N., et al.**: Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. *Arthritis Rheum*, 2008, 59, s. 996–1001.
- 7 **Sherlock, M. E., et al.**: Infliximab induced psoriasis and psoriasisform skin lesions in pediatric Crohn disease and potential association with IL-23 receptor polymorphisms. *J Pediatr Gastroenterol Nutr*, 2013, 56, s. 512–518.
- 8 **Inman, R. D. – Chiu, B.**: Early cytokine profiles in the joint define pathogenesis and severity of arthritis in Chlamydia induced arthritis in rats. *Arthritis Rheum*, 2006, 54, s. 499–507.
- 9 **Pariser, D. M., et al.**: National Psoriasis Foundation clinical consensus on disease severity. *Arch Dermatol*, 2007, 143, s. 239–242.
- 10 **Brown, G., et al.**: Tumor necrosis factor-alpha inhibitor-induced psoriasis: systematic review of clinical features, histopathological findings and management experiences. *Am Acad Dermatol*, 2017, 76, s. 334–341.
- 11 **Ko, J. M., et al.**: Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. *J Dermatol Treat*, 2009, 20, s. 100–108.
- 12 **Braun, J., et al.**: Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis. 2 year results from the randomised phase III MEASURE 1 study. *Ann Rheum Dis*, 2017, 76, s. 1070–1077.
- 13 **Pavelka, K., et al.**: MEASURE 2: Secukinumab provides rapid and sustained relief from key clinical symptoms of active ankylosing spondylitis in TNFi-naïve patients through 5 years. Abstrakt, EULAR Kodaň 2022.
- 14 **Apaydin, H., et al.**: Secukinumab can treat psoriasis induced by anti-TNF-alpha therapy in patients with ankylosing spondylitis: Case series. *Int J Rheum Dis*, 2020, 23, s. 454–456.
- 15 **Gkalpakiotis, S., et al.**: Adalimumab biosimilar-induced severe paradoxical palmoplantar pustulosis in patient with psoriasis and psoriatic arthritis successfully treated with ixekizumab. *Dermatol Ther*, 2020, 12, s. 605–609.

Terapeutický přínos tofacitinibu u nemocných s juvenilní idiopatickou artritidou

doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha

- 1 **Ruperto, N. – Brunner, H. I. – Zuber, Z., et al.**: Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study. *Pediatr Rheumatol Online J*, 2017, 15, s. 86.
- 2 **Ruperto, N. – Brunner, H. I. – Synoverska, O., et al.**: Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, with drawal phase 3 randomised trial. *Lancet*, 2021, 398, s. 1984–1996.

Tofacitinib a riziko vzniku nádorů: výsledky studie STAR-RA u nemocných s revmatoidní artritidou

doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha

- 1 **Safiri, S. – Kolahi, A. A. – Hoy, D., et al.**: Global, regional and national burden of rheumatoid arthritis 1990–2017: a systematic analysis of the Global Burden of Disease study 2017. *Ann Rheum Dis*, 2019, 78, s. 1463–1471.
- 2 **Pfizer Shares Co-Primary Endpoint Results from Post-Marketing Required Safety Study of XELJANZ (tofacitinib) in Subjects with Rheumatoid Arthritis (RA).** Dostupné z: <https://www.pfizer.com/news/press-release/press-release-detail/pfizer-shares-co-primary-endpoint-results-post-marketing>, vyhledáno 12. 7. 2022.
- 3 **Ytterberg, S. R. – Bhatt, D. L. – Mikuls, T. R., et al.**: Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. *N Engl J Med*, 2022, 386, s. 316–326.
- 4 **Initial safety trial results find increased risk of serious heart-related problems and cancer with arthritis and ulcerative colitis medicine Xeljanz, Xeljanz XR (tofacitinib).** FDA, 2021. Dostupné z: <https://www.fda.gov/drugs/drug-safety-and-availability/initial-safety-trial-results-find-increased-risk-serious-heart-related-problems-and-cancer-arthritis>, vyhledáno 12. 7. 2022.
- 5 **Xeljanz (tofacitinib) increased risk of major adverse cardiovascular events and malignancies with use of tofacitinib relative to TNF-alpha inhibitors.** EMA, 2021. Dostupné z: <https://www.ema.europa.eu/en/medicines/dhpc/xeljanz-tofacitinib-increased-risk-major-adverse-cardiovascular-events-malignancies-use-tofacitinib>, vyhledáno 12. 7. 2022.
- 6 **Khosrow-Khavar, F. – Desai, R. J. – Lee, H., et al.**: Tofacitinib and risk of malignancy: results from the Safety of Tofacitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) Study. *Arthritis Rheumatol*, 2022, doi: 10.1002/art.42250.

Subkutánní metotrexát v léčbě revmatoidní artritidy

doc. MUDr. Mária Filková, Ph.D. Revmatologický ústav, Praha

- 1 **Smolen, J. S. – Landewe, R. B. M. – Bijlsma, J. W. J., et al.**: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. *Ann Rheum Dis*, 2020, 79, s. 685–699.
- 2 **Burmester, G. R. – Kivitz, A. J. – Kupper, et al.**: Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. *Ann Rheum Dis*, 2015, 74, s. 1037–1044.
- 3 **Taylor, P. C. – Balsa Criado, A. – Mongey, A. B., et al.**: How to get the most from methotrexate (MTX) treatment for your rheumatoid arthritis patient? MTX in the treat-to-target strategy. *J Clin Med*, 2019, 8, s. 515.
- 4 **Bathon, J. M. – Martin, R. W. – Fleischmann, R., et al.**: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. *N Engl J Med*, 2000, 343, s. 1586–1593.
- 5 **van der Heijde, D. – Klareskog, L. – Rodriguez-Valverde, et al.**: Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. *Arthritis Rheum*, 2006, 54, s. 1063–1074.
- 6 **Breedveld, F. C. – Weisman, M. H. – Kavanaugh, A. F., et al.**: The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. *Arthritis Rheum*, 2006, 54, s. 26–37.
- 7 **Singh, J. A. – Hossain, A. – Mudano, A. S., et al.**: Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. *Cochrane Database Syst Rev*, 2017, 5, CD012657.
- 8 **Rezaei, H. – Saevarsdottir, S. – Forslind, K., et al.**: In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial. *Ann Rheum Dis*, 2012, 71, s. 186–191.
- 9 **Lee, J. – Pelkey, R. – Gubitosa, J.**: Comparing healthcare costs associated with oral and subcutaneous methotrexate or biologic therapy for rheumatoid arthritis in the United States. *Am Health Drug Benefits*, 2017, 10, s. 42–49.
- 10 **Kiely, P. – Busby, A. D. – Nikiforou, E., et al.**: Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts. *BMJ Open*, 2019, 9, e028466.
- 11 **Johnson, T. M. – Sayles, H. R. – Baker, J. F., et al.**: Investigating changes in disease activity as a mediator of cardiovascular risk reduction with methotrexate use in rheumatoid arthritis. *Ann Rheum Dis*, 2021, 80, s. 1385–1392.
- 12 **Brown, P. M. – Pratt, A. G. – Isaacs, J. D.**: Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. *Nat Rev Rheumatol*, 2016, 12, s. 731–742.
- 13 **Hamilton, R. A. – Kremer, J. M.**: Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. *Br J Rheum*, 1997, 36, s. 86–90.
- 14 **Schiff, M. H. – Jaffe, J. S. – Freundlich, B.**: Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥ 15 mg may be overcome with subcutaneous administration. *Ann Rheum Dis*, 2014, 73, s. 1549–1551.
- 15 **Dalrymple, J. M. – Stamp, L. K. – O'Donnell, J. L., et al.**: Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. *Arthritis Rheum*, 2008, 58, s. 3299–3308.
- 16 **Jain, S. – Dhir, V. – Aggarwal, A., et al.**: Comparison of two dose escalation strategies of methotrexate in active rheumatoid arthritis: a multicentre, parallel group, randomised controlled trial. *Ann Rheum Dis*, 2021, 80, s. 1376–1384.
- 17 **O'Dell, J. R. – Curtis, J. R. – Mikuls, T. R., et al.**: Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial. *Arthritis Rheum*, 2013, 65, s. 1985–1994.
- 18 **Verschuere, P. – De Cock, D. – Corluy, L., et al.**: Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. *Ann Rheum Dis*, 2015, 74, s. 27–34.
- 19 **Moreland, L. W. – O'Dell, J. R. – Paulus, H. E., et al.**: A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. *Arthritis Rheum*, 2012, 64, s. 2824–2835.
- 20 **Goekoop-Ruiterman, Y. P. – de Vries-Bouwstra, J. K., et al.**: Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. *Arthritis Rheum*, 2008, 58, s. S126–S135.
- 21 **Kavanaugh, A. – van Vollenhoven, R. F. – Fleischmann, R., et al.**: Testing treat-to-target outcomes with initial methotrexate monotherapy

compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis. *Ann Rheum Dis*, 2018, 77, s. 289–292.

22 Schiff, M. – Koo, J. – Jin, E., et al.: Usability and acceptability of the abatacept pre-filled autoinjector for the subcutaneous treatment of rheumatoid arthritis. *Adv Ther*, 2016, 33, s. 199–213.

23 Pichlmeier, U. – Heuer, K. U.: Subcutaneous administration of methotrexate with a pre-filled autoinjector pen results in a higher relative bioavailability compared with oral administration of methotrexate. *Clin Experiment Rheumatol*, 2014, 32, s. 563–571.

24 Braun, J. – Kastner, P. – Flaxenberg, P., et al.: Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results

of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. *Arthritis Rheum*, 2008, 58, s. 73–81.

25 Bujur, A. M. – Janjua, S. – LaValley, M. P., et al.: Comparison of oral versus parenteral methotrexate in the treatment of rheumatoid arthritis: A meta-analysis. *PLoS One*, 2019, 14, e0221823.

26 Mainman, H. – McClaren, E. – Heycock, C., et al.: When should we use parenteral methotrexate? *Clin Rheumatol*, 2010, 29, s. 1093–1098.

27 Hameed, B. – Jones, H.: Subcutaneous methotrexate is well tolerated and superior to oral methotrexate in the treatment of rheumatoid arthritis. *Int J Rheum Dis*, 2010, 13, s. e83–e84.

28 Bingham, S. J. – Buch, M. H. – Lindsay, S., et al.: Parenteral methotrexate should be given before biological therapy. *Rheumatology*, 2003, 42, s. 1009–1010.

29 Harris, E. – Ng, B.: Using subcutaneous methotrexate to prolong duration of methotrexate therapy in rheumatoid arthritis. *Eur J Rheumatol*, 2018, 5, s. 85–91.

30 Ng, B. – Chu, A.: Factors associated with methotrexate dosing and therapeutic decisions in veterans with rheumatoid arthritis. *Clin Rheumatol*, 2014, 33, s. 21–30.

31 Rutkowska-Sak, L. – Reil-Bakalarska, M. – Lisowska, B.: Oral vs. subcutaneous low-dose methotrexate treatment in reducing gastrointestinal side effects. *Rheumatologia*, 2009, 47, s. 207–211.

32 Taylor, M. C. – Balsa Criado, A. – Mongey, A. B. – Avouac, J. – Marotte, H. – Filková, M.: *Optimizing methotrexate treatment for rheumatoid arthritis*. Springer, 2020.

Risankizumab v léčbě psoriatické artritidy

prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha

1 Helliwell, P. S. – Rudeman, E. M.: Natural history, prognosis, and socioeconomic aspects of psoriatic arthritis. *Rheum Dis Clin North Am*, 2015, 41, s. 581–591.

2 Gossec, L. – Baraliakos, X. – Kerschbaumer, A., et al.: EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. *Ann Rheum Dis*, 2020, 79, s. 700–771.

3 Ogdie, A. – Coates, L. – Gladman, D., et al.: Treatment guidelines in psoriatic arthritis. *Rheumatology*, 2020, 59, s. 37–46.

4 van der Berg, W. B. – McInnes, I. B.: TH 17 cells and IL 17 a – focus on immunopathogenesis and immunotherapeutics. *Semin Arthritis Rheum*, 2013, 43, s. 158–170.

5 Mease, P. J.: Inhibition of interleukin-17, interleukin-23 and the TH 17 cell pathway in the treatment of psoriatic arthritis and psoriasis. *Curr Opin Rheumatol*, 2015, 27, s. 127–133.

6 Kristensen, L. E. – Keiserman, M. – Papp, K., et al.: Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPSAKE 1 trial. *Ann Rheum Dis*, 2021, 0, s. 1–7.

7 Oster, A. – Bosch, F. – Papp, K., et al.: Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double blind, phase 3 KEEPSAKE trial. *Ann Rheum Dis*, 2021, s. 1–8.

8 Yang, K. – Oak, A. S. W. – Elewski, B. E., et al.: Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review. *Am J Clin Dermatol*, 2021, 22, s. 173–192.

9 Mease, P. – Rahman, P. – Gottlieb, A. B., et al.: Guselkumab in biologic naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. *Lancet*, 2020, 395, s. 1126–1136.

10 Deodhar, A. – Helliwell, P. S., et al.: Guselkumab in patients with active

psoriatic arthritis who were biologic naive or had previously received TNF alpha inhibitor treatment, DISCOVER 1 study. *Lancet*, 2020, 395, s. 1115–1125.

11 Nash, P. – Kirkham, B. – Okada, M., et al.: Ixekizumab for the treatment of patients with active psoriatic arthritis and inadequate response to TNF inhibitors. *Lancet*, 2017, 389, s. 2317–2327.

12 EMA

13 Nogales, K. E. – Brasington, R. D. – Bowcock, A. M.: New insights into the pathogenesis and genetics of psoriatic arthritis. *Nat Clin Pract Rheumatol*, 2009, 5, s. 83–91.

14 Rahimi, H. – Ritchlin, C.: Altered bone biology in psoriatic arthritis. *Curr Rheumatol Rep*, 2012, 14, s. 349–357.

15 Lories, R. J. – McInnes, I. B.: Primed for inflammation: enthesis-resident T cells. *Nat Med*, 2012, 18, s. 1018–1019.

Biobetter – novinka (nejen) u revmatologů – reportáž

1 D'Amico, F. – Solitano, V. – Aletaha, D., et al.: Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus. *Autoimmunity Reviews*, 2021, 20, doi.org/10.1016/j.autrev.2021.102849.

2 Westhovens, R. – Wiland, P. – Zawadzki, M., et al.: Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial. *Rheumatology*, 2021, 60, s. 2277–2287.

3 Schreiber, S. – Ben-Horin, S. – Leszczyszyn, J., et al.: Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease. *Gastroenterology*, 2021, 160, s. 2340–2353.

Biobetters – nový pojem v oblasti biologických léků

doc. MUDr. Karel Urbánek, Ph.D. Ústav farmakologie LF UP a FN Olomouc

1 Strojil, J.: Biosimilars – specifika schvalovacího procesu v EU. *Klin Farmakol Farm*, 2014, 28, s. 14–18.

2 Sandeep, V. – Parveen, J. – Chauhan, P.: Biobetters: The better biologics and their regulatory overview. *Int J Drug Regulat Affairs*, 2016, 4, s. 13–20.

3 Torres-Obreque, K. M. – Menegueti, G. P. – Muso-Cachumba, J. J., et al.: Building better biobetters: From fundamentals to industrial application. *Drug Discov Today*, 2022, 27, s. 65–81.

4 Viola, M. – Sequeira, J. – Seica, R., et al.: Subcutaneous delivery of monoclonal antibodies: How do we get there? *J Control Release*, 2018, 286, s. 301–314.

5 Hamuro, L. – Kijanka, G. – Kinderman, F., et al.: Perspectives on subcutaneous route of administration as an immunogenicity risk factor for therapeutic proteins. *J Pharm Sci*, 2017, 106, s. 2946–2954.

6 Kim, H. – Alten, R. – Cummings, F., et al.: Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters. *MABs*, 2021, 13, s. 1868078.

7 Schreiber, S. – Ben-Horin, S. – Leszczyszyn, J., et al.: Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease. *Gastroenterology*, 2021, 160, s. 2340–2353.

8 Iannone, F. – Conti, F. – Cauli, A., et al.: Subcutaneously-administered infliximab in the management of rheumatoid arthritis: a short narrative review of current clinical evidence. *J Inflamm Res*, 2022, 15, s. 3259–3267.

9 Westhovens, R. – Wiland, P. – Zawadzki, M., et al.: Efficacy,

pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial. *Rheumatology*, 2021, 60, s. 2277–2287.

10 Combe, B. – Allanore, Y. – Alten, R., et al.: Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials. *Arthritis Res Ther*, 2021, 23, s. 119.

11 Yoo, D. H. – Westhovens, R. – Ben-Horin, S., et al.: Development of a subcutaneous formulation of CT-P13 (infliximab): Maintenance subcutaneous administration may elicit lower immunogenicity compared to intravenous treatment [abstract]. *Arthritis Rheumatol*, 2018, 70, suppl. 10.

Filgotinib – novinka v léčbě pacientů s revmatoidní artritidou – reportáž

1 Genovese, M. C. – Kalunian, K. – Gottenberg, J. E., et al.: Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial. *JAMA*, 2019, 322, s. 315–325.

2 Combe, B. – Kivitz, A. – Tanaka, Y., et al.: Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. *Ann Rheum Dis*, 2021, 80, s. 848–858.

3 Westhovens, R. – Rigby, W. F. C. – van der Heijde, D., et al.: Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. *Ann Rheum Dis*, 2021, 80, s. 727–738.

4 Di Paolo, J. A., et al.: ACR 2019, abstrakt 059, poster.

5 Winthrop, K. L., Tanaka, Y. – Takeuchi, T., et al.: Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years. *Ann Rheum Dis*, 2022, 81, s. 184–192.

6 Souhrn údajů o přípravku Jyseleca, EMA.

Metamizol v léčbě muskuloskeletální bolesti

MUDr. Marta Olejárová, CSc. Revmatologický ústav a Revmatologická klinika 1. LF UK, Praha

1 SPC. Dostupné z: <https://www.sukl.cz/modules/medication/detail.php?kod=0216736>, vyhledáno 16. 8. 2022.

2 Marhofer, D. – Jaksch, W. – Aigmüller, T., et al.: Schmerztherapie in der Schwangerschaft. *Schmerz*, 2021, 35, s. 382–390.

3 Albrecht, K. – Marschall, U. – Callhoff, J.: Prescription of analgesics in patients with rheumatic diseases in Germany: A claims data analysis. *Z Rheumatol*, 2021, 80, suppl. 2, s. 68–75.

4 Kötter, T. – da Costa, B. R. – Fässler, M., et al.: Metamizole-associated adverse events: a systematic review and meta-analysis. *PLoS One*, 2015, 10, s. e0122918.

5 Ibáñez, L. – Vidal, X. – Ballarín, E., et al.: Agranulocytosis associated with dipyrone (metamizol). *Eur J Clin Pharmacol*, 2005, 60, s. 821–829.

Význam včasného zahájení biologické léčby u pacientů s revmatoidní artritidou

MUDr. Radoslav Roman II. interní klinika, revmatologická ambulance, Fakultní nemocnice u sv. Anny v Brně

- Smolen, J. S. – Aletaha, D. – Barton, A., et al.: Rheumatoid arthritis. Rheumatoid arthritis. *Nat Rev Dis Primers*, 2018, 4, 18001, <https://doi.org/10.1038/nrdp.2018.1>.
- Pavelka, K. – Vencovský, J. – Horák, P.: *Revmatologie*. Maxdorf, Praha, 2018.
- West, S. G., et al.: *Rheumatology Secrets*. Elsevier, 2020, s. 118–130.
- Petrová, N. – Prajzlerová, K. – Vencovský, J. – Šenolt, L. – Filková, M.: The pre-clinical phase of rheumatoid arthritis: From risk factors to prevention of arthritis. *Autoimmun Rev*, 2021, 20, s. 10279.
- Filková, M.: Klinicky suspektní artralgie: současný pohled na preklinickou fázi revmatoidní artritidy. *Čes Revmatol*, 2018, 26, s. 162–170.
- van Steenberghe, H. W. – Aletaha, D., et al.: EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis. *Ann Rheum Dis*, 2017, 76, s. 491–496.
- Kay, J. – Upchurch, K. S.: ACR/EULAR 2010 rheumatoid arthritis classification criteria. *Rheumatology*, 2012, 51, suppl. 6, s. vi5–9.
- Šenolt, L. – Mann, H. – Závada, J. – Pavelka, K. – Vencovský, J.: Doporučení České revmatologické společnosti pro farmakologickou léčbu revmatoidní artritidy 2017, s. 1–31. Dostupné z: https://www.revmatologicka-spolecnost.cz/resources/dokumenty/DP_RA_Senolt_2017.pdf, vyhledáno 12. 8. 2022.
- Boers, M.: Understanding the window of opportunity concept in early rheumatoid arthritis. *Arthritis Rheum*, 2003, 48, s. 1771–1774.
- van Nies, J. A. B. – Tsonaka, R.: Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: Does a window of opportunity exist? Results on the Leiden Early Arthritis Clinic and ESPOLR cohorts. *Ann Rheum Dis*, 2015, 74, s. 806–812.
- Akdemir, G. – Heimens, L. – Bergstra, S. A., et al.: Clinical and radiological outcomes of 5-year drug-free remission-steered treatment in patients with early arthritis: IMPROVED study. *Ann Rheum Dis*, 2018, 77, s. 111–118.
- van der Linden, M. P. M. – leCessie, S., et al.: Long-term impact of delay in assessment of patients with early arthritis. *Arthritis Rheum*, 2010, 62, s. 3537–3546.
- Smolen, J. S. – Breedveld, F. C. – Burmester, G. R., et al.: Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. *Ann Rheum Dis*, 2016, 75, s. 3–15.
- Smolen, J. S. – Landewé, R. B. M. – Bijlsma, J. W. J., et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. *Ann Rheum Dis*, 2020, 79, s. S685–S699.
- Šenolt, L.: Revmatoidní artritida. *Vnitř Léč*, 2018, 64, s. 98–106.
- Felson, D. T. – Smolen, J. S. – Wells, G., et al.: American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. *Ann Rheum Dis*, 2011, 70, s. 404–413.
- Šenolt, L.: Revmatoidní artritida. *Vnitřní lékařství*, 2018, 64, s. 98–108. Dostupné z: https://www.casopisvnitrnilekarstvi.cz/artkey/vnl-201802-0002_rheumatoid-arthritis.php, vyhledáno 12. 8. 2022.
- Smolen, J., et al.: Update of the EULAR recommendations on the management of rheumatoid arthritis. EN-RA-1-6_pop-up_page_v2(9 June)_Yin, s. 1–23. Dostupné z: <https://cdn.doctorsonly.co.il/2022/06/9dda0a9b-a4e0-49d9-9892-4de28fa0e62a.pdf>, vyhledáno 12. 8. 2022.
- Hetland, M. L. – Haavardsholm, E. A. – Rudin, A., et al.: OP0018 A multicenter randomized study in early rheumatoid arthritis to compare active conventional therapy versus three biological treatments: 24 week efficacy results of the NORD-STAR trial. *Ann Rheum Dis*, 2020, 79, s. 13–14. Dostupné z: https://ard.bmj.com/content/anrheumdis/79/Suppl_1/13.full.pdf, vyhledáno 12. 8. 2022.
- FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. Approved uses also being limited to certain patients. 2021. Dostupné z: <https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death>, vyhledáno 12. 8. 2022.
- Pharmacovigilance Risk Assessment Committee (PRAC). Draft agenda for the meeting on 07-10 June 2021. EMA/PRAC/319890/2021, s. 1–89. Dostupné z: https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-7-10-june-2021_en.pdf, vyhledáno 12. 8. 2022.
- Winthrop, K. L. – Cohen, S. B.: Oral surveillance and JAK inhibitor safety: the theory of relativity. *Nat Rev Rheumatol*, 2022, 18, s. 301–304.
- Ytterberg, S. R. – Bhatt, D. L. – Mikuls, T. R., et al.: Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. *N Engl J Med*, 2022, 386, s. 316–326.
- Souhrn údajů o přípravku XELJANZ. Dostupné z: <https://www.sukl.cz/modules/medication/detail.php?code=0222098&tab=prices>, vyhledáno 12. 8. 2022.
- EMA starts safety review of Janus kinase inhibitors for inflammatory disorders. Dostupné z: <https://www.ema.europa.eu/en/news/ema-starts-safety-review-janus-kinase-inhibitors-inflammatory-disorders>, vyhledáno 12. 8. 2022.

Dieta a revmatická onemocnění

MUDr. Jiří Vejmelka Interní klinika 3. LF UK a FTN, Praha

Mgr. Lucie Růžičková vedoucí nutriční terapeutka VFN, Praha

doc. MUDr. Pavel Kohout, Ph.D. Interní klinika 3. LF UK a FTN, Praha

- Minihane, A. M. – Vinoy, S. – Russell, W. R., et al.: Low-grade inflammation, diet composition and health: Current research evidence and its translation. *Br J Nutr*, 2015, 114, s. 999–1012.
- Roager, H. M. – Licht, T. R.: Microbial tryptophan catabolites in health and disease. *Nat Commun*, 2018, 9, s. 3294.
- de Sire, A. – de Sire, R. – Petito, V., et al.: The role of physical exercise on gut microbiota modulation in older people with osteoarthritis. *Nutrients*, 2020, 12, s. 574.
- Scher, J. U. – Sczesnak, A. – Longman, R. S., et al.: Expansion of intestinal prevotella copri correlates with enhanced susceptibility to arthritis. *Elife*, 2013, 2, s. e01202.
- Koeth, R. A. – Wang, Z. – Levison, B. S., et al.: Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes the atherosclerosis. *Nat Med*, 2013, 19, s. 576–585.
- Bach Knudsen, K. E.: Microbial degradation of whole-grain complex carbohydrates and impact on short-chain fatty acids and health. *Adv Nutr*, 2015, 6, s. 206–213.
- Slavin, J.: Fiber and prebiotics: mechanisms and health benefits. *Nutrients*, 2013, 5, s. 1417–1435.
- Samraj, A. N. – Pearce, O. M. – Laubli, H., et al.: A redmeat-derived glycan promotes inflammation and cancer progression. *Proc Natl Acad Sci USA*, 2015, 112, s. 542–547.
- Mensinga, T. T. – Sips, A. J. – Rompelberg, C. J., et al.: Potato glycoalkaloids and adverse effects in humans: an ascending dose study. *Regul Toxicol Pharmacol*, 2005, 41, s. 66–72.
- Bustamante, M. F. – Agustin-Perez, M. – Cedola, F., et al.: Design of an anti-inflammatory diet (ITIS diet) for patients with rheumatoid arthritis. *Contemp Clin Trials Commun*, 2020, 17, s. 100524.
- Rondanelli, M. – Perdoni, F. – Peroni, G., et al.: Ideal food pyramid for patients with rheumatoid arthritis: A narrative review. *Clin Nutr*, 2021, 40, s. 661–689.
- Gioxari, A. – Kalliora, A. C. – Marantidou, F., et al.: Intake of ω -3 polyunsaturated fatty acids in patients with rheumatoid arthritis: A systematic review and meta-analysis. *Nutrition*, 2018, 45, s. 114–124.
- Matsumoto, Y. – Sugioka, Y. – Tada, M., et al.: Monounsaturated fatty acids might be key factors in the Mediterranean diet that suppress rheumatoid arthritis disease activity: The TOMORROW study. *Clin Nutr*, 2018, 37, s. 675–680.
- Alunno, A. – Carubbi, F. – Bartoloni, E., et al.: Diet in rheumatoid arthritis versus systemic lupus erythematosus: Any differences? *Nutrients*, 2021, 13, s. 772.
- Elkan, A. C. – Sjöberg, B. – Kolsrud, B., et al.: Gluten-free vegan diet induces decreased LDL and oxidized LDL levels and raised atheroprotective natural antibodies against phosphorylcholine in patients with rheumatoid arthritis: a randomized study. *Arthritis Res Ther*, 2008, 10, s. R34.
- Hafstrom, I. – Ringertz, B. – Spångberg, A., et al.: A vegan diet free of gluten improves the signs and symptoms of rheumatoid arthritis: The effects on arthritis correlate with a reduction in antibodies to food antigens. *Rheumatol*, 2001, 40, s. 1175–1179.
- Potter, E. – Brienesse, S. C. – Walker, M. M., et al.: Effect of the gluten-free diet on cardiovascular risk factors in patients with coeliac disease: A systematic review. *J Gastroenterol Hepatol*, 2017, 33, s. 781–791.
- Lebwohl, B. – Cao, Y. – Zong, G., et al.: Long term gluten consumption in adults without celiac disease and risk of coronary heart disease: Prospective cohort study. *BMJ*, 2017, 357, s. j1892.
- Goharifar, H. – Faezi, S. T. – Paragomi, P., et al.: The effect of Ramadan fasting on quiescent systemic lupus erythematosus (SLE) patients' disease activity, health quality of life and lipid profile: A pilot study. *Rheumatol Int*, 2015, 35, s. 1409–1414.
- Grassi, D. – Desideri, G. – Ferri, C.: Flavonoids: antioxidants against atherosclerosis. *Nutrition*, 2010, 2, s. 889–902.
- Cuervo, A. – Hevia, A. – López, P., et al.: Association of polyphenols from oranges and apples with specific intestinal microorganisms in systemic lupus erythematosus patients. *Nutrition*, 2015, 7, s. 1301–1317.
- Emu, Q. – Ezhang, H. – Luo, X. M.: SLE: another autoimmune disorder influenced by microbes and diet? *Front Immunol*, 2015, 6, s. 608.
- Facchini, F. – Chen, Y. D. – Hollenbeck, C. B., et al.: Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. *JAMA*, 1991, 266, s. 3008–3011.
- Fam, A. G.: Gout, diet, and the insulin resistance syndrome. *J Rheumatol*, 2002, 29, s. 1350–1355.
- Yokose, C. – McCormick, N. – Choi, H. K.: The role of diet in hyperuricemia and gout. *Curr Opin Rheumatol*, 2021, 33, s. 135–144.
- Sacks, F. M. – Svetkey, L. P. – Vollmer, W. M., et al.: Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. *N Engl J Med*, 2001, 344, s. 3–10.
- Birchough, G. – Schroeder, B. O. – Bäckhed, F., et al.: Dietary destabilisation of the balance between the microbiota and the colonic mucus barrier. *Gut Microbes*, 2019, 10, s. 246–250.
- Thomas, S. – Browne, H. – Mobasher, A., et al.: What is the evidence for a role for diet and nutrition in osteoarthritis? *Rheumatology*, 2018, 57, suppl. 4, s. iv61–iv74.
- Dourado, E. – Ferro, M. – SousaGuerreiro, C., et al.: Diet as a modulator of intestinal microbiota in rheumatoid arthritis. *Nutrients*, 2020, 12, s. 3504.
- Minamino, H. – Katsushima, M. – Torii, M., et al.: Serum vitamin D status inversely associates with a prevalence of severe sarcopenia among female patients with rheumatoid arthritis. *Sci Rep*, 2021, 11, s. 20485.
- Islam, M. A. – Khandker, S. S. – Kotly, P. J., et al.: Immunomodulatory effects of diet and nutrients in systemic lupus erythematosus (SLE): a systematic review. *Front Immunol*, 2020, 11, s. 1477.
- Burlui, A. M. – Cardoneanu, A. – Macovei, L. A., et al.: diet in scleroderma: is there a need for intervention? *Diagnostics*, 2021, 11, s. 2118.
- Singh, J. A. – Guyatt, G. – Ogdie, A., et al.: Special Article 2018: American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. *Arthritis Rheumatol*, 2019, 71, s. 5–32.
- Popa, S. L. – Dumitrascu, D. I. – Brata, V. D., et al.: Nutrition in spondyloarthritis and related immune-mediated disorders. *Nutrients*, 2022, 14, s. 1278.
- Carubbi, F. – Alunno, A. – Mai, F., et al.: Adherence to the Mediterranean diet and the impact on clinical features in primary Sjögren's syndrome. *Clin Exp Rheumatol*, 2021, 39, suppl. 133, s. 190–196.
- Rizzoli, R. – Bischoff-Ferrari, H. – Dawson-Hughes, B., et al.: Nutrition and bone health in women after the menopause. *Women's Health*, 2014, 10, s. 599–608.